Healthy Living/WellnessFDA requests investigation of cholesterol drug's neurocognitive risks The FDA has asked that Sanofi and Regeneron test a new cholesterol-fighting drug, alirocumab, for the possibility of neurocognitive inference or damage.by Tabitha Laffernis
Healthy Living/WellnessPfizer recalls antidepressant Effexor after wrong drug found in bottleby Pierre Dumont
Healthy Living/WellnessYoung skin cancer survivors at higher risk of different cancers in the futureby Tabitha Laffernis
Healthy Living/WellnessFree birth control does not encourage unsafe sex, study showsby Tabitha Laffernis
Healthy Living/WellnessAntibiotics overuse in U.S. hospitals is a growing problem, CDC warnsby Rhodilee Jean Dolor
iPadOS Stage Manager Unlocks Powerful Multitasking, External Display Support, and Smart Window Management